CAJ | 학술논문

目的：探讨抗病毒治疗丙型肝炎肝硬化代偿期患者的临床疗效。方法收集我院2012年6月至2014年6月丙型肝炎肝硬化代偿期146例患者资料，将患者按照随机数表法分为两组，各73例，A1组患者给予聚乙二醇干扰素a-2a+利巴韦林治疗，A2组患者给予常规保肝治疗。比较两组患者治疗12、24周后肝功能指标。结果两组患者治疗12周后，TBIL、ALT、AST以及HCV-RNA水平与治疗前比较，差异均无统计学意义（均P＞0.05）；治疗24周后，A1组患者TBIL、ALT、AST以及HCV-RNA水平明显优于A2组，差异均有统计学意义（均P＜0.05）。结论聚乙二醇干扰素 a-2a+利巴韦林治疗丙型肝炎肝硬化代偿期患者，针对病毒复制可表现出明显的抑制作用，患者的肝脏功能可获得明显改善，效果明显。
목적：탐토항병독치료병형간염간경화대상기환자적림상료효。방법수집아원2012년6월지2014년6월병형간염간경화대상기146례환자자료，장환자안조수궤수표법분위량조，각73례，A1조환자급여취을이순간우소a-2a+리파위림치료，A2조환자급여상규보간치료。비교량조환자치료12、24주후간공능지표。결과량조환자치료12주후，TBIL、ALT、AST이급HCV-RNA수평여치료전비교，차이균무통계학의의（균P＞0.05）；치료24주후，A1조환자TBIL、ALT、AST이급HCV-RNA수평명현우우A2조，차이균유통계학의의（균P＜0.05）。결론취을이순간우소 a-2a+리파위림치료병형간염간경화대상기환자，침대병독복제가표현출명현적억제작용，환자적간장공능가획득명현개선，효과명현。
Objective To explore the clinical efficacy of antiviral therapy in hepatitis cirrhosis decompensation period patients.Methods Patients were colected in our hospital from 2012 June to 2014 data in June,hepatitis C cirrhosis 146 cases,according to the random number table method into two groups,each 73 cases,group A1 treated with pegylated interferon and ribavirin in the treatment of a-2a+,A2 group was treated with routine treatment. Comparison of two groups of treatment of liver function index 12,24 weeks after.Results The patients in the two groups after 12 weeks treatment,the comparison of TBIL,ALT,AST and HCV-RNA levels and before treatment,no significant difference(P>0.05);after 24 weeks of treatment,patients in group A1 TBIL,ALT,AST and HCV-RNA levels were significantly better than those in A2 group,the difference was statisticaly significant(P<0.05).Conclusion Pegylated interferon a-2a+ and ribavirin in the treatment of patients with hepatitis C cirrhosis,according to viral replication can be showed an obvious inhibition of liver function of patients can be improved evidently,the effect is obvious.